In a mouse xenograft model of non-high grade ovarian cancer (IGROV-1 cells), CX-4945 treatment prevented tumor growth, decreased vascular area and proliferative index, and prevented mRNA expression of TNF, IL-6, and VEGF. This evidence concerns the gene IL6 and ovarian cancer.